Core Viewpoint - The company has experienced significant revenue growth in 2024, but net profit has declined due to intense price competition in the spice industry [2] Group 1: Financial Performance - In 2024, the company achieved a revenue of 797 million yuan, representing a year-on-year increase of 26.42%, while net profit attributable to shareholders was 56 million yuan, down 30.51% [2] - In Q1 2024, the company reported a record revenue of 262 million yuan and a net profit of approximately 82.17 million yuan, with a non-recurring net profit of 38.20 million yuan, marking a year-on-year growth of 120.8% [2] Group 2: Production Capacity and Expansion - The first phase of the "Yaxiang Biotechnology (Thailand) Co., Ltd. Production Base Project" commenced production in November 2024, with the Thai factory achieving normal full-load production [2] - The first phase capacity includes 1,000 tons of vanillin, 200 tons of oak moss, and other products, with a second phase expected to be completed around August 2025 [3] - A new synthetic vanillin production line is planned in Thailand, which will have an annual capacity of 4,000 tons [3] Group 3: Strategic Investments - The company plans to acquire 10% equity in Centrome Inc. for 30 million USD to expand sales channels and market share in the U.S. [3] - This investment is expected to enhance the company's international influence and complement its U.S. subsidiary's operations [3] Group 4: Market Strategy - The establishment of the Thai base allows the company to diversify its product structure and increase production capacity while avoiding tariff impacts [4] - The company is actively exploring new product layouts to meet diverse market demands, including the introduction of ambroxan, a fragrance ingredient commonly used in perfumes [4]

Group 1: Financial Performance - The company's net profit for 2024 is expected to decline due to four main factors: increased fixed asset depreciation, a 37% year-on-year increase in sales team size leading to higher sales expenses, increased R&D investment, and a structural decline in gross margin of core products due to intensified market competition [2][3] - In Q1 2025, the company reported a net profit growth of approximately 360%, attributed to investment income of about 40 million yuan and the efficient operation of the Thai production base [3] Group 2: Operational Insights - The Thai factory achieved approximately 90 million yuan in revenue and 19 million yuan in net profit in Q1 2025, primarily producing vanillin and cooling agents [3] - Long-term contracts account for about 80% of the company's total revenue, with pricing strategies adjusted based on market supply and demand dynamics [3][4] Group 3: Expansion and Product Development - The first phase of the Thai base is fully operational, with the second phase expected to be completed around August 2025, and the third phase in preliminary planning [3] - The company is actively exploring new product developments, such as ambroxan, to meet diverse market and consumer demands [4] - Strategic investment in ABT shares aims to strengthen sales channels and enhance market competitiveness [4]

3.公司未来在研发方面有何规划？是否会加大对新产品或新技 术的研发投入？ 证券代码：300886 证券简称：华业香料 答：尊敬的投资者，您好！未来，公司将继续秉持以市场为导向 的原则，聚焦技术迭代、新品开发、质量提升三大核心任务，坚定不 移地推进技术攻关工作。包括持续优化研发管理体系，提升创新效 能；前瞻性推动产品技术迭代，稳固主导产品的技术优势；强化新产 品技术开发力度，培育丰富的"产品树"；提升产品质量水平，进一 步增强产品竞争力；积极布局新兴赛道技术研发，大力推进生物发酵 产品技术研发等。感谢您的关注！ 安徽华业香料股份有限公司 4.高管您好。请问贵公司本期财务报告中，盈利表现如何？谢谢。 答：尊敬的投资者，您好！2024年，公司实现营业收入34,518.05 万元，同比增长28.12%；实现归属于上市公司股东的净利润2,208.99 万元，同比增长659.83%。2025年一季度，公司实现营业收入9,779.32 万元，同比增长24.06%；实现归属于上市公司股东的净利润1,145.28 万元，同比增长94.50%。感谢您的关注！ 投资者关系活动记录表 5.研发费用大幅增加，会为公司带来哪些具体的技术 ...

证券代码：920016 证券简称：中草香料 公告编号：2025-049 安徽中草香料股份有限公司 关于投资者关系活动记录表的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 投资者关系活动类别 √特定对象调研 √业绩说明会 □媒体采访 活动地点：（一）全景网"投资者互动平台"（https://ir.p5w.net）以网络方式 召开业绩说明会。（二）线上会议。 参会单位及人员：（一）业绩说明会：通过网络方式参加 2024 年年度报告暨 2025 年第一季度报告业绩说明会的投资者。（二）线上会议：中泰研究、犁得尔 基金、非马投资、太平基金、观富资产、源乘基金、蜂巢基金、凯丰投资、紫阁 投资（以上排名不分先后）。 上市公司接待人员：（一）业绩说明会：公司董事长、总经理：李莉女士； 财务总监：赵慧女士；董事、董事会秘书：赵娅女士；保荐代表人：邵鸿波先生、 □现场参观 □新闻发布会 □分析师会议 □路演活动 □其他 二、 投资者关系活动情况 活动时间：2025 年 4 月 30 日 王三标先生。（二）线 ...

在天津武清区合成生物技术全国重点实验室内，科研人员通过基因编辑技术，将玫瑰中调控玫瑰醇合成 的关键基因"嫁接"至酿酒酵母中，同时精准敲除其代谢干扰路径。经过改造的酵母菌如同获得"玫瑰基 因密码"，能在发酵罐中持续产出与天然玫瑰完全一致的芳香分子。 当实验室里的酵母菌取代玫瑰花田成为香水原料的"生产主力"，合成生物学技术正为人类续写千年"寻 香"故事的全新篇章。天津大学合成生物前沿研究院近日宣布，其团队利用合成生物学技术，成功在酵 母菌中重构玫瑰香气物质合成路径，建成高效"细胞工厂"，以颠覆性方式实现玫瑰醇的微生物合成。 这一成果不仅破解了天然玫瑰香精依赖种植、提取难、成本高的百年难题，更标志着我国在天然产物合 成领域迈出关键一步。 "这相当于给微生物装上定制化'生产手册'，让它们像植物一样自然合成目标产物。"团队副研究员姚明 东介绍。目前，单批次10吨级发酵罐运行5天即可产出相当于300亩玫瑰园的原料。传统方法需要 9000亩（相当于12605个足球场）的玫瑰园才能获得的产量，现在只需要占地面积不到5平方米、2层 楼高的发酵罐就能搞定。 相较于传统蒸馏萃取工艺，该技术使玫瑰醇生产效率提升数十倍，生产成本降低8 ...

Core Viewpoint - The company, Aipu Flavor Group Co., Ltd., has released its first quarter financial report for 2025, ensuring the accuracy and completeness of the information provided [1][8]. Financial Data Summary - The financial statements for the first quarter of 2025 are unaudited, with the company confirming that there are no significant changes in accounting data and financial indicators [2][7]. - The company has not recognized any non-recurring gains or losses during the reporting period [2][3]. Shareholder Information - As of March 31, 2025, the company has repurchased 7,600,000 shares, representing 1.9831% of the total share capital [4]. Operational Changes - The company has shifted its sales strategy from a mixed model of direct sales and distribution to a purely direct sales model, enhancing customer autonomy and market penetration without adversely affecting business operations [7].

Financial Overview - The company achieved significant growth in Q1 2025, with total revenue reaching 262 million yuan, a year-on-year increase of 50.28% [1] - The net profit attributable to shareholders was 82.17 million yuan, a substantial year-on-year increase of 361.70% [1] - The net profit after deducting non-recurring items was 38.20 million yuan, reflecting a year-on-year growth of 120.80% [1] Profitability Analysis - The company's gross margin was 31.58%, an increase of 18.52 percentage points year-on-year [2] - The net profit margin reached 31.35%, showing a significant year-on-year increase of 210.16 percentage points [2] - This indicates notable improvements in product value addition and service quality [2] Cost and Expenses - Despite revenue and profit growth, the proportion of the company's three expenses (selling, administrative, and financial expenses) to revenue increased from 9.46% in the same period last year to 12.68%, a rise of 34.05% [3] - This suggests potential pressure on cost control during operations [3] Asset and Liability Situation - As of the end of the reporting period, the company's cash and cash equivalents amounted to 256 million yuan, a decrease of 31.57% year-on-year [4] - Accounts receivable increased to 292 million yuan, a year-on-year growth of 44.09%, with accounts receivable to profit ratio reaching 524.82%, necessitating close monitoring of collection [4] - Interest-bearing liabilities also increased to 345 million yuan, a year-on-year rise of 73.42% [4] Per Share Indicators - The net asset per share was 21.20 yuan, a year-on-year increase of 9.17% [5] - Earnings per share were 1.02 yuan, reflecting a year-on-year growth of 363.64% [5] - Operating cash flow per share was 0.49 yuan, a significant year-on-year increase of 405.36% [5] Business Model and Financing Dividends - The company's performance primarily relies on R&D, equity financing, and capital expenditures [6] - Since its listing, the total financing amount has reached 727 million yuan, with total dividends distributed amounting to 40.40 million yuan, resulting in a dividend financing ratio of only 0.06 [6] - Overall, while the company showed excellent performance in Q1 2025, the rising expense ratio and rapid growth in accounts receivable warrant further attention from investors [6]

证券代码：603020 证券简称：爱普股份 公告编号：2025-021 爱普香料集团股份有限公司 2025 年第一季度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所上市公司自律监管指引第 3 号---行业信息披露 第十 四号---食品制造》的相关规定，现将爱普香料集团股份有限公司(以下简称"公 司")2025 年第一季度主要经营数据（未经审计）公告如下： 一、报告期经营情况 1、按照产品类别分类情况 单位：万元 币种：人民币 | 产品类别 | 2025 年第一季度 | 2024 年第一季度 | 同比变动(%) | | --- | --- | --- | --- | | 香精 | 15,946.00 | 15,324.58 | 4.06 | | 香料 | 3,663.69 | 4,731.35 | -22.57 | | 食品配料 | 40,565.31 | 54,103.62 | -25.02 | | 小计 | 60,175.00 | 74,159.55 | -18.86 | 2、按照销售 ...

证券代码：920016 证券简称：中草香料 公告编号：2025-048 安徽中草香料股份有限公司 三、 投资者关系活动主要内容 在本次投资者关系活动中公司向各位投资者简要介绍了公司的基本情况、 主营业务、产品特性等内容。本次投资者关系活动的主要问题及问题回复概要 如下： □业绩说明会 □媒体采访 √现场参观 □新闻发布会 □分析师会议 □路演活动 □其他 1、公司 2024 年度产品收入构成 关于投资者关系活动记录表的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 投资者关系活动类别 √特定对象调研 二、 投资者关系活动情况 活动时间：2025 年 4 月 26 日 活动地点：安徽中草新材料有限公司会议室、厂区 参会单位及人员：洪顺资本、申万宏源研究、东北证券（以上排名不分先后） 上市公司接待人员：董事、董事会秘书赵娅女士 回答：公司产品可以分为凉味剂系列、合成香料系列、天然香料系列，可 以应用于食品、饮料、日化、医药、烟草、饲料等领域，公司产品基本流向产 业链下游企业。 5、预计何时释放新 ...

智通财经4月28日电，亚香股份(301220.SZ)公告称，2025年第一季度营业收入为2.62亿元，同比增长 50.28%；归属于上市公司股东的净利润为8216.81万元，同比增长361.70%。净利润增长主要是本期收入 增加及处置子公司股权的投资收益增加所致。 亚香股份：一季度净利润同比增长361.70% ...